{"canonical":"https://abierto.us/vendors/atux-iskay-group-llc-c7jpq5f3uuh7","key":"C7JPQ5F3UUH7","name":"ATUX ISKAY GROUP LLC","uei":"C7JPQ5F3UUH7","city":"PLAINSBORO","state":"NJ","awards":2,"obligated":"355000.00","notices_won":0,"top_agency_name":"National Institutes of Health","top_naics":"541715","cage":"88C46","parent_name":"ATUX ISKAY GROUP LLC","also_known_as":[],"country":"USA","actions":6,"first_action":"2024-02-12","last_action":"2025-02-11","breakdowns":{"naics":[{"key":"541715","name":null,"awards":2,"obligated":"355000.00"}],"places":[{"key":"NJ","name":null,"awards":2,"obligated":"355000.00"}],"agencies":[{"key":"7529","name":"National Institutes of Health","awards":2,"obligated":"355000.00"}],"set_asides":[{"key":"SMALL BUSINESS SET ASIDE - TOTAL","name":null,"awards":2,"obligated":"355000.00"}],"award_types":[{"key":"DEFINITIVE CONTRACT","name":null,"awards":2,"obligated":"355000.00"}],"competition":[{"key":"FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES","name":null,"awards":2,"obligated":"355000.00"}],"product_service_codes":[{"key":"AN12","name":null,"awards":2,"obligated":"355000.00"}]},"awards_list":[{"award_key":"CONT_AWD_75N91024C00009_7529_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75N91024C00009_7529_-NONE-_-NONE-/","piid":"75N91024C00009","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"C7JPQ5F3UUH7","recipient_name":"ATUX ISKAY GROUP LLC","recipient_uei":"C7JPQ5F3UUH7","recipient_cage":"88C46","recipient_city":"PLAINSBORO","recipient_state":"NJ","sub_name":"National Institutes of Health","office_name":"NIH NCI","office_key":"o-75N910","first_action_date":"2024-02-12","last_action_date":"2025-02-11","actions":4,"obligated":"355000.00","current_total_value":"355000.00","potential_total_value":"355000.00","naics":"541715","psc":"AN12","extent_competed":"FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES","set_aside":"SMALL BUSINESS SET ASIDE - TOTAL","offers_received":27,"description":"SBIR CONCEPT AWARD - THERAPEUTICS - SULFONYL-UREA AND SULFONAMIDE PP2A ACTIVATORS AS MYCN AMPLIFIED NEUROBLASTOMA (NBL) THERAPEUTICS","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null},{"award_key":"CONT_AWD_75N91023C00038_7529_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75N91023C00038_7529_-NONE-_-NONE-/","piid":"75N91023C00038","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"C7JPQ5F3UUH7","recipient_name":"ATUX ISKAY GROUP LLC","recipient_uei":"C7JPQ5F3UUH7","recipient_cage":"88C46","recipient_city":"PLAINSBORO","recipient_state":"NJ","sub_name":"National Institutes of Health","office_name":"NIH NCI","office_key":"o-75N910","first_action_date":"2024-09-12","last_action_date":"2024-10-16","actions":2,"obligated":"0","current_total_value":"400000.00","potential_total_value":"400000.00","naics":"541715","psc":"AN12","extent_competed":"FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES","set_aside":"SMALL BUSINESS SET ASIDE - TOTAL","offers_received":7,"description":"SBIR PHASE I TOPIC #446 - DEVELOPMENT OF SENOTHERAPEUTIC AGENTS FOR CANCER TREATMENT","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null}],"awards_total":2,"awards_page":1,"won":[],"won_total":0,"solicitations_won":[]}